Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615731 | 1.00 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL6444859 | 1.00 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL13964503 | 1.00 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL30537712 | 0.89 | SPHK1 (0.46) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL25305199 | 0.87 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL30484720 | 0.87 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL10211199 | 0.87 | SPHK1 (0.45) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL19088552 | 0.86 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL8252763 | 0.86 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 | |
| SCHEMBL11959795 | 0.86 | SPHK1 (0.44) | SPHK1BRD4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209102-B2 | Heterocyclic compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4489738-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-26 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-1189874-B1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | LILLY SA (ES) | 2005-01-26 | — | — | EP | disclosed |
| US-6504052-B1 | 2-carboxycyclopropyl glycine derivatives, used as agonists of glutamate receptors for prophylaxis of psychological and nervous system disorders; anxiolytics; antidepressants; drug abuse; anticonvulsant, analgesic and antiemetic agents | ELI LILLY AND COMPANY | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425522-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | SPHK1 2922/4885BRD4 236/4885CHRM2 4874/4885 |
| US-12209102-B2 | Heterocyclic compounds and uses thereof | TP53, HRAS, KRAS | SPHK1 2922/4885BRD4 236/4885CHRM2 4874/4885 |
| US-20240425525-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | SPHK1 2922/4885BRD4 236/4885CHRM2 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.